No definite guidelines exist for the management of nongastric MALT lymphoma. Retrospective series have included patients treated with different modalities, and excellent cause-specific and overall survival have been demonstrated, independent of the type of treatment adopted.
Table 1: Sensitivity of 18-FDG PET/CT in MALT Lymphomas in Recent Reports
Table 2: Recommended Site-Specific Workup in Nongastric MALT Lymphomas
Table 3: Antibiotic-Induced Lymphoma Remission in Ocular Adnexa and Cutaneous MALT Lymphomas
Figure: Regimens Used in the IELSG-19 Randomized Study
The group of marginal zone B-cell lymphomas (MZL) comprises three different entities, extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (currently called MALT lymphoma), nodal marginal zone B-cell lymphoma (previously known as monocytoid lymphoma), and splenic marginal zone B-cell lymphoma (with or without circulating villous lymphocytes).[1-3] Primary splenic and nodal MZLs are rare, each comprising approximately less than 2% of lymphomas, while the extranodal MZL of MALT type is not uncommon, representing approximately 7% to 8% of the total number of non-Hodgkin lymphoma cases.
MALT lymphoma B cells have somatically mutated IGHV genes in all cases, with a pattern of somatic hypermutation and intraclonal variations suggesting that the tumor cells have undergone antigen selection and that their expansion may remain antigen-driven.[5,6] Indeed, MALT lymphoma usually arises in mucosal sites where lymphocytes are not normally present and where MALT is acquired in response either to autoimmune processes, such as Hashimoto thyroiditis or SjÃ¶gren syndrome, or to chronic infectious conditions. It is believed that, in the context of a persistent antigenic stimulation, successive genetic abnormalities can progressively hit a B-cell clone among the reactive B cells of the chronic inflammatory tissue and give rise to a MALT lymphoma.
The stomach is the most common site of localization, accounting for about one-third of cases, and the remission of most gastric MALT lymphomas after eradication of Helicobacter pylori strongly indicates a pathogenetic link between tumor cell proliferation and chronic H pylori–induced inflammation. Several studies have confirmed the high efficacy of H pylori eradication in gastric MALT lymphomas; many of these report long-lasting remissions, with no need for more aggressive therapies in most patients.
Other microbial agents have been implicated in the pathogenesis of MALT lymphomas arising in other extranodal sites, such as the skin (Borrelia burgdorferi), the ocular adnexa (Chlamydophila psittaci), and the small intestine (Campylobacter jejuni).
The prevalence of hepatitis C virus (HCV) has been reported to be higher in patients with MZLs, including MALT lymphomas, than in controls, suggesting a possible causative role for the viral agent.
At least four recurrent chromosomal aberrations-the apparently mutually exclusive translocations t(11;18)(q21;q21), t(1;14)(p22;q32), and t(14;18)(q32;q21), and the 6q23.3 deletion-have been reported in MALT lymphomas; these affect the same signaling pathway, resulting in the activation of nuclear factor kappa B, a transcription factor with a central role in immunity, inflammation, and apoptosis.[8-14] The occurrence of the translocations varies according to the anatomic site. Moreover, there are suggestions that the incidence and distribution of these translocations varies with geography, possibly reflecting different genetic backgrounds of the patients or of infectious agents.
Besides playing a role in lymphomagenesis, these site-specific biologic differences may influence outcome and therapeutic approaches. Indeed, while antibiotic therapy is nowadays well established as the standard of care in patients with H pylori–associated gastric MALT lymphoma, much less is known about the value of antibiotic therapy in nongastric MALT lymphomas, and their standard treatment is less well defined.
The diagnosis of MALT lymphoma should be made in accordance with the current World Health Organization (WHO) classification, and it is recommended that the diagnosis be confirmed by an expert hematopathologist. Differentiation from other indolent lymphomas that can present at extranodal sites is not always clear-cut and should be confirmed; hence, a minimum immunohistochemistry panel should include CD20, CD10, CD5, and cyclin D1. The presence of lymphoepithelial lesions is not essential for the diagnosis, and their presence is not pathognomonic, as these can be seen both in some reactive conditions and in other extranodal lymphomas. Since scattered large cells are usually present, ruling out a potential associated large B-cell lymphoma is crucial. While the presence of the chromosomal translocation t(11;18)(q21;q21) may give an indication of the likelihood of response of a gastric lymphoma to H pylori eradication alone, no consistent prognostic markers have been identified that could affect the initial clinical management in nongastric MALT lymphoma.
MALT lymphomas only seldom form prominent tumor masses and are often difficult to distinguish from the inflammatory lesion that underlies the acquisition of MALT from which the lymphoma arises. The presenting symptoms are largely related to the primary location. Only a small minority of patients present with elevated lactate dehydrogenase (LDH) or Î²2-microglobulin levels, and constitutional B symptoms are extremely rare.[16-20]
MALT lymphoma usually remains localized for a prolonged period within the tissue of origin, but spreading to multiple sites is not uncommon, and presentation with disseminated disease is reported in up to one-fourth of cases and seems more common in nongastric MALT cases.[18,21-23] Bone marrow involvement is reported in up to 20% of cases.[20,24] In a retrospective survey from the International Extranodal Lymphoma Study Group (IELSG), the nongastric MALT lymphoma patients with disease classed as stage IV because of bone marrow or lymph node involvement had an inferior overall survival rate compared with those with multiple mucosal localizations only. The finding that dissemination to multiple mucosal sites does not change the outcome has also been shown in other series, and most patients have a favorable outcome, with overall survival usually higher than 80% at 5 years.[21,25]
The most common nongastric MALT lymphoma sites are the salivary glands, skin, orbits and conjunctiva, lung, thyroid, upper airways, breast, other GI sites, and liver.[18,19,21,23] The anatomic site may have prognostic relevance because of organ-specific clinical problems, but because different genetic lesions may be associated with different localizations, it is possible that the different sites have a distinct natural history. In a study from Princess Margaret Hospital in Toronto evaluating the long-term outcome of 167 patients with localized (stage IE and IIE) MALT lymphoma treated with involved-field radiotherapy, gastric and thyroid lymphomas had a significantly better outcome, and distant failures were more common for other sites. In general, despite frequent relapses, MALT lymphomas most often maintain an indolent course. In the above-mentioned study, the 10-year recurrence-free rate was 76%, the overall survival rate was 87%, and the cause-specific survival rate was 98%. Histologic transformation to large-cell lymphoma is reported in 4% to 20% of cases, most often as a late event and independent of dissemination.[21,25-27]
Because of the risk of occult disseminated disease, extensive work-up procedures are recommended in all MALT lymphomas, irrespective of their presentation site, and should comprise a history and physical examination (including lymph node regions, eye and ear, nose and throat, liver and spleen clinical evaluations); complete blood cell counts and basic biochemical studies, including evaluation of renal and liver function; LDH and Î²2-microglobulin levels; serum protein immunofixation; human immunodeficiency virus (HIV), HCV, and hepatitis B virus (HBV) serologies; CT scan of the chest, abdomen, and pelvis; and bone marrow aspirate and biopsy. We also consider gastroduodenal endoscopy with multiple biopsies to exclude a concomitant gastric involvement, particularly when localized radiotherapy is planned. The value of a positron emission tomography (PET) scan is still controversial, with uncertain clinical consequences; although it is not recommended, there is mounting evidence that most nongastric sites are usually PET-positive (Table 1).[29-43] Additional, site-specific procedures are summarized in Table 2.
There is no clear consensus for the treatment of patients with gastric MALT lymphoma who require further therapy beyond H pylori eradication or who have extensive disease. No definite guidelines exist for the management of nongastric lymphoma (nor for H pylori–negative cases). Several retrospective series showed no significant survival difference between patients who received different initial treatments (including chemotherapy alone, surgery alone, surgery with additional chemotherapy, and radiation therapy).[18,21,23,25]
A modest dose of involved-field radiotherapy (25–35 Gy) gives excellent disease control.[26,44] The emerging literature on localized MALT lymphomas confirms a high rate of local control, with a high proportion of patients likely to be cured of the disease. Indeed, radiotherapy has become a standard treatment, at least in North America, for patients with stage I/II MALT lymphoma of the stomach without evidence of H pylori infection or with persistent lymphoma after antibiotics, as well as for most nongastric localized presentations.[45-54] The use of radiotherapy in this setting has been recommended by the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Modern radiotherapy planning techniques, such as three-dimensional conformal radiotherapy and intensity-modulated radiotherapy, facilitate the determination of the clinical target volume, reducing the toxicity that is related to the irradiation of nontarget organs.[56,57] In general, the moderate doses of radiation required for cure are associated with mild and reversible side effects and a low risk of long-term toxicity, although special considerations are needed for particular localizations, such as the eye or the lung.[26,56,58,59]
When systemic treatment is needed, enrollment in controlled clinical trials is advisable since, although chemotherapy (and/ or immunotherapy with anti-CD20 monoclonal antibodies) is an obvious choice, there only a few compounds and regimens tested specifically in the setting of MALT lymphoma.
Oral alkylating agents (either cyclophosphamide or chlorambucil) can result in a high rate of disease control. The purine analogs fludarabine and cladribine have demonstrated some antitumor activity in phase II studies, but they may be associated with an increased risk of secondary myelodysplastic syndrome. The activity of the anti-CD20 monoclonal antibody rituximab has also been demonstrated in a phase II study (with a response rate of about 70%), and this may represent an additional option for the treatment of systemic disease. The efficacy of the combination of rituximab and chlorambucil has been explored in the IELSG-19 randomized study in gastric MALT lymphomas in which antibiotics have failed, and in nongastric MALT lymphomas.[62,63] Compared with chlorambucil alone, and with rituximab alone, the combination of chlorambucil plus rituximab resulted in increased complete remission and event-free survival rates, but the 5-year overall survival was nearly identical in all treatment arms.[63,64] This combination is the only one thus far tested in a large randomized study.
A polychemotherapy regimen comprising chlorambucil/mitoxantrone/prednisone has been reported to be effective and well tolerated in MALT lymphoma, irrespective of localization. Excellent activity with acceptable toxicity has also been reported for short-term front-line treatment with bendamustine plus rituximab in a phase II trial.
More aggressive anthracycline-containing chemotherapy should be reserved for patients with high tumor burden (bulky masses, unfavorable International Prognostic Index). Finally, radiotherapy can be an effective therapy that provides local disease control for some patients with stage III or IV disease.
Although H pylori eradication using antibiotic regimens combined with proton-pump inhibitors is nowadays the standard front-line therapy for patients with H pylori–associated gastric MALT lymphoma, the role of antibiotic therapy in patients with nongastric MALT lymphoma is much less well defined.
Anecdotal reports linking H pylori to the growth of nongastric MALT lymphoma and describing regressions of nongastric MALT lymphomas in H pylori–infected patients after H pylori eradication have been published,[68-70] but a larger series from Austria of 77 patients with extragastric MALT lymphomas showed that this approach is not effective in the majority of patients with nongastric localization, in whom the incidence of H pylori infection was similar to the infection rate in the healthy Austrian population (and significantly lower than the incidence observed in gastric lymphomas).
After H pylori, C psittaci is the most thoroughly studied of the other bacteria reported to have a potential pathogenetic role in MALT lymphoma. Evidence supporting a pathogenetic association between this bacterial agent and the development of MALT lymphoma of the ocular adnexa includes the identification of chlamydial antigens in tumor tissue by immunohistochemistry, detection of bacterial DNA in tumor biopsy specimens, visualization of the bacteria within tumor-infiltrating macrophages by electron microscopy, and the isolation of the bacteria from conjunctival swabs and the peripheral blood of patients.[72-77] Moreover, development of metachronous C psittaci–related lymphomas in the same patient after prolonged exposure to an infected animal has been described. The finding that C psittaci has been detected in up to ~80% of Italian patients with ocular adnexa MALT lymphoma provided the rationale for the antibiotic treatment of localized lesions.[74,75] In addition, eradication of C psittaci infection using doxycycline as targeted therapy for patients with ocular adnexa MALT lymphoma resulted in lymphoma regression in approximately 50% of patients, including in those with multiple treatment failures, previously irradiated lesions, or regional lymph node involvement.[76,77]
Following the first demonstration that doxycycline treatment may cause tumor regression in patients with C psittaci–associated lesions, subsequent reports on the efficacy of antibiotics in ocular adnexa lymphoma showed conflicting data and apparent geographic variations.[75,78] Indeed, the prevalence of C psittaci infection in ocular adnexal lymphoma varies among countries and among different regions within the same country. It is higher in Italy, Austria, Korea, and Germany; and it isvirtually absent in Japan, France, and China.[75,79]
A prospective international phase II study was then conducted by the IELSG, in which 34 untreated patients with stage 1 ocular adnexal MALT lymphoma had doxycycline treatment (100 mg orally twice daily for 3 weeks) and were assessed for chlamydial eradication and lymphoma response. In this study, C psittaci DNA was detected in nearly 90% of the lymphoma biopsy specimens, while no other Chlamydiaceae were detected. Twenty-nine patients had C psittaci DNA in baseline swabs or blood samples and were evaluable for chlamydial eradication, which was achieved in 48%. Lymphoma regression was complete in 6 patients and partial in 16, with an overall response rate of 65%. At a median follow-up of 37 months, the 5-year progression-free survival was 55%. C psittaci eradication was associated with improved response rate and progression-free survival. Indeed, 86% of patients who achieved successful eradication of the bacteria attained a major and durable lymphoma regression. These findings confirmed the critical role played by C psittaci in sustaining the lymphoma growth. In this study, a consistent concordance between C psittaci detected in tumor tissue and C psittaci on conjunctival swabs indicated that conjunctival swabs may be a simple, noninvasive tool for monitoring the infection.
Overall, doxycycline treatment has been studied in about 120 patients with ocular adnexa MALT lymphoma (Table 3), with responses seen in about half of these. The best responses are usually achieved within 6 months. However, analogous to H pylori eradication in gastric MALT lymphoma, in some patients, responses are slow and gradual and may require up to 36 months. How long a patient can be safely observed after doxycycline treatment before starting a different treatment remains to be clarified.
Of interest, lymphoma regression after doxycycline treatment has been observed in some lymphomas where there is no evidence of C psittaci, as well as in cases where this treatment failed to eradicate the C psittaci infection.[72,77,81] This contrasts with results in the better-studied gastric MALT lymphoma (where H pylori–negative patients are generally unresponsive to antibiotic treatment) and might suggest that other doxycycline-sensitive microorganisms may be linked with the lymphoma. The optimal administration schedule for doxycycline also remains to be defined,[72,81] and further investigations are warranted to identify other potential infective agents and to improve antibiotic efficacy. Moreover, mechanisms leading to lymphoma regression have yet to be elucidated, and direct anti-inflammatory or antiproliferative effects of doxycycline cannot be ruled out.
Some antineoplastic activity of macrolides has been shown in murine cancer models, providing the basis for an exploratory study of a 6-month oral clarithromycin regimen in 11 patients with ocular adnexa MALT lymphoma. In this study, five patients who had been previously unsuccessfully treated with doxycycline responded to the clarithromycin therapy. Because lymphoma responses were seen in patients who had persistent disease several months after eradication of the chronic infection, the authors concluded that an antitumor or immunomodulatory effect, rather than the direct antimicrobial activity of clarithromycin, might be the cause of the observed lymphoma regressions.
B burgdorferi chronic infection may induce a typical B-cell infiltration known as cutaneous “pseudolymphoma.” This spirochetal agent has also been reported to have a potential pathogenetic role in marginal zone lymphomas of the skin, but its association with cutaneous lymphomas presents striking geographic variations. A few case reports have documented that the eradication of B burgdorferi following ceftriaxone therapy appeared to have resulted in regression of an associated cutaneous marginal zone lymphoma; therefore, the demonstration of a B burgdorferi infection may be sought in endemic areas where it may have some therapeutic implications. However, the evidence comes from such a limited number of patients (Table 3) that no sound recommendations can be made.
Several other case reports and small series-recently reviewed by Kiesewetter and Raderer-have described the potential association of various chronic infections with MALT lymphomas localized in the lungs, parotid and salivary glands, breast, thyroid, and bladder; however, the results of some of these studies were controversial. No conclusion can be drawn from the available information on antibiotic treatment in these lymphomas; the published data are scanty and possibly biased by the preferential publication of positive results.
Along with the above-mentioned bacterial infections, high rates of HCV infection have been reported in MALT lymphomas, particularly in patients with subcutaneous or salivary gland localization.[7,84,85] Although there are important geographical differences in HCV infection, responses after antiviral therapy have been observed, and anti-HCV treatment should be considered in patients with active chronic infection.
Immunoproliferative small intestinal disease (IPSID), previously also known as alpha-heavy-chain disease or Mediterranean lymphoma, is a special subtype of MALT lymphoma.[1,87,88] The typical and peculiar feature of IPSID is the production of alpha heavy chain. The latter is secreted and, in up to 75% of cases, is detected in the serum, urine, saliva, and duodenal fluid; in the remaining cases, the alpha heavy chain is not secreted but it is still demonstrable by immunohistochemistry.
IPSID typically affects young adults, predominantly males. Although it is endemic in the Middle East, especially in the Mediterranean area, IPSID can also be diagnosed in industrialized Western countries, usually in immigrants from the area where it is endemic.
IPSID has a prolonged natural history, often over many years, including a potentially reversible early phase; the disease is usually confined to the abdomen. If left untreated, the lymphoma can undergo a histologic transformation to a diffuse large B-cell lymphoma. Surgery has no therapeutic role, since the lymphoma usually presents with diffuse involvement of the intestine. In its early phases, IPSID can be treated with sustained antibiotic therapy (eg, tetracycline or metronidazole and ampicillin for at least 6 months), which can lead to a durable remission. These results suggest a role for an infectious agent, and C jejuni is, so far, the best candidate. Indeed, at an early stage, antibiotic treatment directed against C jejuni may lead to lymphoma regression. Anthracycline-containing regimens, combined with nutritional support plus antibiotics to control diarrhea and malabsorption, represent the best chance of cure in the advanced phases.
No definite guidelines exist for the management of nongastric MALT lymphoma. Retrospective series have included patients treated with different modalities, and excellent cause-specific and overall survival have been demonstrated, independent of the type of treatment adopted.[18,21,23,25]
Involved-field radiotherapy encompassing the involved organ alone, with a dose of 24 Gy to 36 Gy,[26,44,56,58] has a well-established role in the treatment of localized lesions. However, there is no clear consensus as to whether radiation is more or less effective than systemic therapy in MALT lymphomas at different locations, and the experience of each center and the patient’s preferences in terms of adverse effects are important parameters to include in the decision-making process.
Because no curative treatment exists, expectant observation is an adequate initial policy in most patients with advanced disease. In general, the treatment should be “patient-tailored,” taking into account the site and stage of the disease, and the clinical characteristics of the individual patient.
When systemic treatment is needed, the use of chemotherapy together with rituximab seems obvious; however, the regimen of choice is controversial, and the combination of rituximab with chlorambucil is the only one that has been tested in a randomized study; the treatment schedules used are described in the Figure.
In comparison with gastric MALT lymphoma, much less is known about the role of antibiotic therapies in nongastric tumors. At present, only the association of C psittaci with ocular adnexal MALT lymphoma has been adequately tested; even so, the promising results of doxycycline therapy still lack long-term follow-up data. Nevertheless, the activity reported by Ferreri et al in untreated patients appears not inferior to that reported with chemotherapy and radiotherapy,[90,91] and the toxicity is negligible, suggesting that upfront doxycycline is a reasonable and effective treatment that can be proposed for patients with stage I C psittaci–positive MALT lymphoma of the ocular adnexa before consideration of more aggressive strategies. This may allow durable remission, avoid adverse effects, and delay more intensive treatments. In all other instances, antibiotic treatment of nongastric lymphomas should be regarded as investigational.
Acknowledgments:The authors would like to thank our colleague Afua Adjeiwaa Mensah (Bellinzona, Switzerland) for manuscript editing. This work was partially supported by the Nelia et Amadeo Barletta Foundation (Lausanne, Switzerland) and by a grant from Oncosuisse (ICP OCS-01356-03-2003).
Financial Disclosure:Dr. Zucca receives research funding from Roche. Drs. Stathis and Bertoni have no significant financial interest in or other relationship with the manufacturer of any product or provider of any service mentioned in this article.
1. Isaacson PG, Chott A, Nakamura S, et al. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). In: Swerdlow S, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. p. 214-17.
2. Campo E, Pileri SA, Jaffe ES, et al. Nodal marginal zone B-cell lymphoma. In: Swerdlow S, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. p. 218-19.
3. Isaacson PG, Piris MA, Berger F, et al. Splenic B-cell marginal zone lymphoma. In: Swerdlow S, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. p. 185-87.
4. The Non-Hodgkin’s Lymphoma Classification Project: A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. Blood. 1997;89:3909-18.
5. Bertoni F, Coiffier B, Salles G, et al. MALT lymphomas: pathogenesis can drive treatment. Oncology (Williston Park). 2011;25:1134-42, 47.
6. Craig VJ, Arnold I, Gerke C, et al. Gastric MALT lymphoma B cells express polyreactive, somatically mutated immunoglobulins. Blood. 2010;115:581-91.
7. Arcaini L, Burcheri S, Rossi A, et al. Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT. Ann Oncol. 2007;18:346-50.
8. Isaacson PG, Du MQ. MALT lymphoma: from morphology to molecules. Nat Rev Cancer. 2004;4:644-53.
9. Jost PJ, Ruland J. Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences and therapeutic implications. Blood. 2007;109:2700-07.
10. Bertoni F, Zucca E. Delving deeper into MALT lymphoma biology. J Clin Invest. 2006;116:22-6.
11. Langel FD, Jain NA, Rossman JS, et al. Multiple protein domains mediate interaction between Bcl10 and MALT1. J Biol Chem. 2008;283:32419-31.
12. Lucas PC, McAllister-Lucas LM Nunez G. NF-kappaB signaling in lymphocytes: a new cast of characters. J Cell Sci. 2004;117:31-9.
13. Baens M, Fevery S, Sagaert X, et al. Selective expansion of marginal zone B cells in Emicro-API2-MALT1 mice is linked to enhanced IkappaB kinase gamma polyubiquitination. Cancer Res. 2006;66:5270-7.
14. Novak U, Rinaldi A, Kwee I, et al. The NF-kB pathway component A20 (TNFAIP3) is commonly inactivated by DNA mutations and deletions in extranodal marginal zone B-cell lymphoma (EMZL). Ann Oncol. 2008;abstract at the 10-ICML.
15. Kwee I, Rancoita PM, Rinaldi A, et al. Genomic profiles of MALT lymphomas: variability across anatomical sites. Haematologica. 2011;96:1064-6.
16. Zucca E, Bertoni F, Roggero E, Cavalli F. The gastric marginal zone B-cell lymphoma of MALT type. Blood. 2000;96:410-19.
17. Pinotti G, Zucca E, Roggero E, et al. Clinical features, treatment and outcome in a series of 93 patients with low-grade gastric MALT lymphoma. Leuk Lymphoma. 1997;26:527-37.
18. Zucca E, Conconi A, Pedrinis E, et al. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood. 2003;101:2489-95.
19. Thieblemont C, Bastion Y, Berger F, et al. Mucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior: analysis of 108 patients. J Clin Oncol. 1997;15:1624-30.
20. Thieblemont C. Clinical presentation and management of marginal zone lymphomas. Hematology (Am Soc Hematol Educ Program). 2005;307-13.
21. de Boer JP, Hiddink RF, Raderer M, et al. Dissemination patterns in nongastric MALT lymphoma. Haematologica. 2008;93:201-06.
22. Thieblemont C, Coiffier B. MALT lymphoma: Sites of presentations, clinical features and staging procedures. In: Zucca E Bertoni F. MALT lymphomas. Georgetown, TX, USA: Landes Bioscience / Kluwer Academic; 2004. p. 60-80.
23. Raderer M, Wohrer S, Streubel B, et al. Assessment of disease dissemination in gastric compared with extragastric mucosa-associated lymphoid tissue lymphoma using extensive staging: a single-center experience. J Clin Oncol. 2006;24:3136-41.
24. Cavalli F, Isaacson PG, Gascoyne RD, Zucca E. MALT lymphomas. Hematology (Am Soc Hematol Educ Program). 2001;241-58.
25. Thieblemont C, Berger F, Dumontet C, et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood. 2000;95:802-6.
26. Goda JS, Gospodarowicz M, Pintilie M, et al. Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy. Cancer. 2010;116:3815-24.
27. Franceschetti S, Conconi A, Von Hohenstaufen KA, et al. Histologic transformation in marginal zone lymphomas. ASH Annual Meeting Abstracts. 2012;120:1571.
28. Dreyling M, Thieblemont C, Gallamini A, et al. ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol. 2013;24:857-77.
29. Beal KP, Yeung HW Yahalom J. FDG-PET scanning for detection and staging of extranodal marginal zone lymphomas of the MALT type: a report of 42 cases. Ann Oncol. 2005;16:473-80.
30. Alinari L, Castellucci P, Elstrom R, et al. 18F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma. Leuk Lymphoma. 2006;47:2096-101.
31. Hoffmann M, Wohrer S, Becherer A, et al. 18F-Fluoro-deoxy-glucose positron emission tomography in lymphoma of mucosa-associated lymphoid tissue: histology makes the difference. Ann Oncol. 2006;17:1761-5.
32. Ambrosini V, Rubello D, Castellucci P, et al. Diagnostic role of 18F-FDG PET in gastric MALT lymphoma. Nucl Med Rev Cent East Eur. 2006;9:37-40.
33. Karam M, Novak L, Cyriac J, et al. Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas. Cancer. 2006;107:175-83.
34. Radan L, Fischer D, Bar-Shalom R, et al. FDG avidity and PET/CT patterns in primary gastric lymphoma. Eur J Nucl Med Mol Imaging. 2008;35:1424-30.
35. Perry C, Herishanu Y, Metzer U, et al. Diagnostic accuracy of PET/CT in patients with extranodal marginal zone MALT lymphoma. Eur J Haematol. 2007;79:205-9.
36. Tsukamoto N, Kojima M, Hasegawa M, et al. The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification. Cancer. 2007;110:652-9.
37. Enomoto K, Hamada K, Inohara H, et al. Mucosa-associated lymphoid tissue lymphoma studied with FDG-PET: a comparison with CT and endoscopic findings. Ann Nucl Med. 2008;22:261-7.
38. Weiler-Sagie M, Bushelev O, Epelbaum R, et al. 18F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med. 2010;51:25-30.
39. Hirose Y, Kaida H, Ishibashi M, et al. Comparison between endoscopic macroscopic classification and F-18 FDG PET findings in gastric mucosa-associated lymphoid tissue lymphoma patients. Clin Nucl Med. 2012;37:152-7.
40. Zhang WD, Guan YB, Li CX, et al. Pulmonary mucosa-associated lymphoid tissue lymphoma: computed tomography and (1)(8)F fluorodeoxyglucose-positron emission tomography/computed tomography imaging findings and follow-up. J Comput Assist Tomogr. 2011;35:608-13.
41. Zanni M, Moulin-Romsee G, Servois V, et al. Value of 18FDG PET scan in staging of ocular adnexal lymphomas: a large single-center experience. Hematology. 2012;17:76-84.
42. Yoon RG, Kim MY, Song JW, et al. Primary endobronchial marginal zone B-cell lymphoma of bronchus-associated lymphoid tissue: CT findings in 7 patients. Korean J Radiol. 2013;14:366-74.
43. Nasser QJ, Pfeiffer ML, Romaguera J, et al. Clinical value of magnetic resonance imaging and other baseline testing for conjunctival mucosa-associated lymphoid tissue lymphoma. Leuk Lymphoma. 2013 Aug 28. [Epub ahead of print]
44. Yahalom J. Patients with H pylori-independent MALT lymphoma are curable with radiotherapy. Oncology (Williston Park). 2011;25:1147-9.
45. Tsang RW, Gospodarowicz MK, Pintilie M, et al. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol. 2003;21:4157-64.
46. Hitchcock S, Ng AK, Fisher DC, et al. Treatment outcome of mucosa-associated lymphoid tissue/marginal zone non-Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys. 2002;52:1058-66.
47. Le QT, Eulau SM, George TI, et al. Primary radiotherapy for localized orbital MALT lymphoma. Int J Radiat Oncol Biol Phys. 2002;52:657-63.
48. Ansell SM, Grant CS, Habermann TM. Primary thyroid lymphoma. Semin Oncol. 1999;26:316-23.
49. Brogi E, Harris NL. Lymphomas of the breast: pathology and clinical behavior. Sem Oncol. 1999;26:357-64.
50. Agulnik M, Tsang R, Baker MA, et al. Malignant lymphoma of mucosa-associated lymphoid tissue of the lacrimal gland: case report and review of literature. Am J Clin Oncol. 2001;24:67-70.
51. Jhavar S, Agarwal JP, Naresh KN, et al. Primary extranodal mucosa associated lymphoid tissue (MALT) lymphoma of the prostate. Leuk Lymphoma. 2001;41:445-9.
52. Suchy BH, Wolf SR. Bilateral mucosa-associated lymphoid tissue lymphoma of the parotid gland. Arch Otolaryngol Head Neck Surg. 2000;126:224-6.
53. Puri DR, Tereffe W, Yahalom J. Low-dose and limited-volume radiotherapy alone for primary dural marginal zone lymphoma: treatment approach and review of published data. Int J Radiat Oncol Biol Phys. 2008;71:1425-35.
54. Milgrom SA, Yahalom J. Indolent non-Hodgkin lymphoma primarily involving the hard palate: outcome following radiotherapy. Leuk Lymphoma. 2013;54:1208-11.
55. National Comprehensive Cancer Network guidelines v. 2.2013: non-Hodgkin lymphoma. Available from: http://www.nccn.org/professionals/physician_gls/PDF/nhl.pdf. Accessed November 11, 2013.
56. Yahalom J. MALT lymphomas: a radiation oncology viewpoint. Ann Hematol. 2001;80(suppl 3):B100-5.
57. Gospodarowicz M, Tsang R. Radiation therapy of mucosa-associated lymphoid tissue (MALT) lymphomas. In: Zucca E. MALT lymphomas. Georgetown, TX, USA: Landes Bioscience / Kluwer Academic; 2004. p. 104-29.
58. Tsang RW, Gospodarowicz MK. Radiation therapy for localized low-grade non-Hodgkin’s lymphomas. Hematol Oncol. 2005;23:10-7.
59. Koch P, Probst A, Berdel WE, et al. Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96). J Clin Oncol. 2005;23:7050-9.
60. Zinzani PL, Stefoni V, Musuraca G, et al. Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma. Cancer. 2004;100:2190-4.
61. Jager G, Hofler G, Linkesch W, Neumeister P. Occurrence of a myelodysplastic syndrome (MDS) during first-line 2-chloro-deoxyadenosine (2-CDA) treatment of a low-grade gastrointestinal MALT lymphoma. Case report and review of the literature. Haematologica. 2004;89:ECR01.
62. Zucca E, Conconi A, Martinelli G, et al. Chlorambucil plus rituximab produces better event-free survival in comparison with chlorambucil alone in the treatment of MALT lymphoma: 5-year analysis of the 2-arms part of the IELSG-19 randomized study. ASH Annual Meeting Abstracts. 2010;116:432.
63. Zucca E, Conconi A, Martinelli G, et al. Chlorambucil plus rituximab produces better event-free and progression-free survival in comparison with chlorambucil or rituximab alone in extranodal marginal zone B-cell lymphoma (MALT lymphoma): results of the IELSG-19 study. Hematological Oncology. 2013;31(S1):97-98.
64. Zucca E, Conconi A, Laszlo D, et al. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study. J Clin Oncol. 2013;31:565-72.
65. Wohrer S, Drach J, Hejna M, et al. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with mitoxantrone, chlorambucil and prednisone (MCP). Ann Oncol. 2003;14:1758-61.
66. Salar A, Domingo-Domenech E, Panizo C, et al. Bendamustine plus rituximab in first line systemic treatment for extranodal MALT lymphoma: final results of phase II trial of the Spanish lymphoma study group (GELTAMO). Hematol Oncol. 2013;31(S1):129-30.
67. Teckie S, Lovie S, Navarett S, Yahalom J. Clinical outcomes and patterns of relapse in 320 patients with early and advanced-stage marginal zone lymphoma: the role of radiotherapy. Hematological Oncology. 2013;31 (S1):130.
68. van den Bosch J, Kropman RF, Blok P Wijermans PW. Disappearance of a mucosa-associated lymphoid tissue (MALT) lymphoma of the urinary bladder after treatment for Helicobacter pylori. Eur J Haematol. 2002;68:187-8.
69. Raderer M, Pfeffel F, Pohl G, et al. Regression of colonic low grade B cell lymphoma of the mucosa associated lymphoid tissue type after eradication of Helicobacter pylori. Gut. 2000;46:133-5.
70. Arima N, Tsudo M. Extragastric mucosa-associated lymphoid tissue lymphoma showing the regression by Helicobacter pylori eradication therapy. Br J Haematol. 2003;120:790-2.
71. Grunberger B, Wohrer S, Streubel B, et al. Antibiotic treatment is not effective in patients infected with Helicobacter pylori suffering from extragastric MALT lymphoma. J Clin Oncol. 2006;24:1370-5.
72. Ferreri AJ, Govi S, Pasini E, et al. Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial. J Clin Oncol. 2012;30:2988-94.
73. Ferreri AJ, Dolcetti R, Magnino S, et al. A woman and her canary: a tale of chlamydiae and lymphomas. J Natl Cancer Inst. 2007;99:1418-9.
74. Ferreri AJ, Guidoboni M, Ponzoni M, et al. Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. J Natl Cancer Inst. 2004;96:586-94.
75. Ferreri AJM, Dolcetti R, Du MQ, et al. Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy. Ann Oncol. 2008;19:835-46.
76. Ferreri AJ, Ponzoni M, Guidoboni M, et al. Regression of ocular adnexal lymphoma following Chlamydia psittaci-eradicating antibiotic therapy. J Clin Oncol. 2005;23:5067-73.
77. Ferreri AJ, Ponzoni M, Guidoboni M, et al. Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial. J Natl Cancer Inst. 2006;98:1375-82.
78. Troch M, Kiesewetter B, Raderer M. Recent developments in nongastric mucosa-associated lymphoid tissue lymphoma. Curr Hematol Malig Rep. 2011;6:216-21.
79. Zucca E, Bertoni F. Chlamydia or not Chlamydia, that is the question: which is the microorganism associated with MALT lymphomas of the ocular adnexa? J Natl Cancer Inst. 2006;98:1348-9.
80. Kiesewetter B, Raderer M. Antibiotic therapy in nongastrointestinal MALT lymphoma: a review of the literature. Blood. 2013;122:1350-7.
81. Kim TM, Kim KH, Lee MJ, et al. First-line therapy with doxycycline in ocular adnexal mucosa-associated lymphoid tissue lymphoma: a retrospective analysis of clinical predictors. Cancer Sci. 2010;101:1199-203.â©82. Govi S, Dognini GP, Licata G, et al. Six-month oral clarithromycin regimen is safe and active in extranodal marginal zone B-cell lymphomas: final results of a single-centre phase II trial. Br J Haematol. 2010;150:226-9.
83. Roggero E, Zucca E, Mainetti C, et al. Eradication of Borrelia burgdorferi infection in primary marginal zone B-cell lymphoma of the skin. Hum Pathol. 2000;31:263-8.
84. Ambrosetti A, Zanotti R, Pattaro C, et al. Most cases of primary salivary mucosa-associated lymphoid tissue lymphoma are associated either with Sjoegren syndrome or hepatitis C virus infection. Br J Haematol. 2004;126:43-9.
85. Paulli M, Arcaini L, Lucioni M, et al. Subcutaneous ‘lipoma-like’ B-cell lymphoma associated with HCV infection: a new presentation of primary extranodal marginal zone B-cell lymphoma of MALT. Ann Oncol. 2010;21:1189-95.
86. Nicolosi Guidicelli S, Lopez-Guillermo A, Falcone U, et al. Hepatitis C virus and GBV-C virus prevalence among patients with B-cell lymphoma in different European regions: a case-control study of the International Extranodal Lymphoma Study Group. Hematol Oncol. 2012;30:137-42.
87. Al-Saleem T, Al-Mondhiry H. Immunoproliferative small intestinal disease (IPSID): a model for mature B-cell neoplasms. Blood. 2005;105:2274-80.
88. Suarez F, Lortholary O, Hermine O, Lecuit M. Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood. 2006;107:3034-44.
89. Lecuit M, Abachin E, Martin A, et al. Immunoproliferative small intestinal disease associated with Campylobacter jejuni. N Engl J Med. 2004;350:239-48.
90. Ben Simon GJ, Cheung N, McKelvie P, et al. Oral chlorambucil for extranodal, marginal zone, B-cell lymphoma of mucosa-associated lymphoid tissue of the orbit. Ophthalmology. 2006;113:1209-13.
91. Ejima Y, Sasaki R, Okamoto Y, et al. Ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiotherapy. Radiother Oncol. 2006;78:6-9.